Deerfield Management Company, L.P. (Series C) Krystal Biotech, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 4,166 shares of KRYS stock, worth $711,302. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,166
Previous 1,605
159.56%
Holding current value
$711,302
Previous $294,000
157.48%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$674 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$487 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$448 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$248 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$169 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.38B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...